Review of tests for monitoring doxorubicin-induced cardiomyopathy - PubMed

Affiliations

• PMID: 8960141
• DOI: 10.1159/000227621

Review

Review of tests for monitoring doxorubicin-induced cardiomyopathy

W I Ganz et al. Oncology. 1996 Nov-Dec.

Abstract

The objective of this review is to make physicians aware of new radionuclide methods to detect cardiac effects of chemotherapeutic drugs. This knowledge is important because of the limitations of the physical examination and the electrocardiogram for detecting early reversible cardiac damage. Presently left ventricular ejection fraction (LVEF) is routinely used to screen for cardiotoxicity. Since LVEF obtained by radionuclide angiocardiography is more accurate than the LVEF estimated by echocardiography, serial radionuclide LVEF monitoring is most commonly used to monitor cardiotoxicity. Diastolic measurements of left ventricular function (such as peak filling rate) are now being added to routine LVEF measurements to enhance standard radionuclide evaluation. This screening test should be done prior to beginning therapy and at appropriate points based on the baseline study, therapy scheme and the patient's clinical status. At some centers, exercise LVEF methods are being used to determine if cardiac reserve is adequate for the patient to tolerate additional chemotherapy when cardiac injury may be present. Previously, endomyocardial biopsy was needed to detect and confirm early anthracycline cardiotoxicity. This invasive test may be replaced by a new noninvasive in vivo method using radioactive monoclonal antibodies against cardiac muscle (indium-111-antimyosin). Because cardiac failure has been associated with adrenergic neuron injury, it has been proposed that radioactive methyliodobenzylguanine may detect the adrenergic abnormality which may predict future development of congestive heart failure or sudden death months after therapy is discontinued. Advantages and disadvantages of these methods in evaluating cardiotoxicity, and an algorithm to optimally monitor antitumor therapy-induced cardiomyopathy are discussed.

Similar articles

• ¹²³ I-MIBG imaging for detection of anthracycline-induced cardiomyopathy.

  Laursen AH, Thune JJ, Hutchings M, Hasbak P, Kjaer A, Elming MB, Ripa RS. Laursen AH, et al. Clin Physiol Funct Imaging. 2018 Mar;38(2):176-185. doi: 10.1111/cpf.12419. Epub 2017 Mar 2. Clin Physiol Funct Imaging. 2018. PMID: 28251781 Review.

• Early detection of anthracycline-induced cardiotoxicity by radionuclide angiocardiography.

  Suzuki J, Yanagisawa A, Shigeyama T, Tsubota J, Yasumura T, Shimoyama K, Ishikawa K. Suzuki J, et al. Angiology. 1999 Jan;50(1):37-45. doi: 10.1177/000331979905000105. Angiology. 1999. PMID: 9924887

• Usefulness of indium-111 antimyosin scintigraphy in confirming myocardial injury in patients with anthracycline-associated left ventricular dysfunction.

  Valdés Olmos RA, ten Bokkel Huinink WW, ten Hoeve RF, van Tinteren H, Bruning PF, van Vlies B, Hoefnagel CA. Valdés Olmos RA, et al. Ann Oncol. 1994 Sep;5(7):617-22. doi: 10.1093/oxfordjournals.annonc.a058933. Ann Oncol. 1994. PMID: 7993837 Clinical Trial.

• Anthracycline-induced cardiomyopathy: long-term effects on myocardial cell integrity, cardiac adrenergic innervation and fatty acid uptake.

  Nousiainen T, Vanninen E, Jantunen E, Remes J, Kuikka J, Hartikainen J. Nousiainen T, et al. Clin Physiol. 2001 Jan;21(1):123-8. doi: 10.1046/j.1365-2281.2001.00292.x. Clin Physiol. 2001. PMID: 11168306

• [Drug-induced myocardial disease--adriamycin cardiotoxicity].

  Wakasugi S. Wakasugi S. Nihon Rinsho. 2000 Jan;58(1):204-11. Nihon Rinsho. 2000. PMID: 10885315 Review. Japanese.

Cited by

• Chemotherapy-induced cardiotoxicity.

  Shaikh AY, Shih JA. Shaikh AY, et al. Curr Heart Fail Rep. 2012 Jun;9(2):117-27. doi: 10.1007/s11897-012-0083-y. Curr Heart Fail Rep. 2012. PMID: 22382639 Review.

• Has LVEF changed beyond chance? Limits of agreement of radiotracer-derived LVEF.

  Wackers FJ. Wackers FJ. J Nucl Cardiol. 2015 Dec;22(6):1244-6. doi: 10.1007/s12350-015-0090-y. Epub 2015 Feb 20. J Nucl Cardiol. 2015. PMID: 25698484 No abstract available.

• Potential Therapeutic Treatments for Doxorubicin-Induced Cardiomyopathy.

  Kabir S, Lingappa N, Mayrovitz H. Kabir S, et al. Cureus. 2022 Jan 12;14(1):e21154. doi: 10.7759/cureus.21154. eCollection 2022 Jan. Cureus. 2022. PMID: 35165604 Free PMC article. Review.

• Anticancer Chemotherapy and it's Anaesthetic Implications (Current Concepts).

  Gehdoo RP. Gehdoo RP. Indian J Anaesth. 2009 Feb;53(1):18-29. Indian J Anaesth. 2009. PMID: 20640073 Free PMC article.

• Luteinizing hormone-releasing hormone targeted poly(methyl vinyl ether maleic acid) nanoparticles for doxorubicin delivery to MCF-7 breast cancer cells.

  Varshosaz J, Jahanian-Najafabadi A, Ghazzavi J. Varshosaz J, et al. IET Nanobiotechnol. 2016 Aug;10(4):206-14. doi: 10.1049/iet-nbt.2015.0056. IET Nanobiotechnol. 2016. PMID: 27463791 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • S. Karger AG, Basel, Switzerland

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information